Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

CJ. Coats, A. Masri, ME. Nassif, R. Barriales-Villa, M. Arad, N. Cardim, L. Choudhury, B. Claggett, HD. Düngen, P. Garcia-Pavia, AA. Hagège, JL. Januzzi, MMY. Lee, GD. Lewis, CS. Ma, MS. Maron, ZM. Miao, M. Michels, I. Olivotto, A. Oreziak, AT....

. 2024 ; 13 (15) : e035993. [pub] 20240726

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019390

BACKGROUND: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). METHODS AND RESULTS: A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5-20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site-interpreted Valsalva left ventricular outflow tract gradient <30 mm Hg with left ventricular ejection fraction (LVEF) ≥50%. End points were evaluated during titration (day 1 to week 8), maintenance (weeks 8-24), and washout (weeks 24-28), and included major adverse cardiac events, new-onset atrial fibrillation, implantable cardioverter-defibrillator discharges, LVEF <50%, and treatment-emergent adverse events. At week 8, 3.6%, 12.9%, 35%, and 48.6% of patients achieved 5-, 10-, 15-, and 20-mg doses, respectively. Baseline characteristics were similar across groups. Aficamten concentration increased by dose and remained stable during maintenance. During the treatment period, LVEF decreased by -0.9% (95% CI, -1.3 to -0.6) per 100 ng/mL aficamten exposure. Seven (4.9%) patients taking aficamten underwent per-protocol dose reduction for site-interpreted LVEF <50%. There were no treatment interruptions or heart failure worsening for LVEF <50%. No major adverse cardiovascular events were associated with aficamten, and treatment-emergent adverse events were similar between treatment groups, including atrial fibrillation. CONCLUSIONS: A site-based dosing algorithm targeting the lowest effective aficamten dose reduced left ventricular outflow tract gradient with a favorable safety profile throughout SEQUOIA-HCM. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05186818.

Assistance Publique Hôpitaux de Paris Département de Cardiologie Hôpital Européen Georges Pompidou Paris France

Beijing Anzhen Hospital Capital Medical University Beijing China

Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston MA

Charité Campus Virchow Klinikum Berlin Germany

Complexo Hospitalario Universitario A Coruña INIBIC CIBERCV ISCIII A Coruña Spain

Cytokinetics Incorporated South San Francisco CA

Department of Cardiology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Department of Cardiology Erasmus Medical Center Cardiovascular Institute Thoraxcenter Rotterdam The Netherlands

Division of Cardiology Department of Medicine Massachusetts General Hospital Harvard Medical School Boston MA

Heart Failure and Biomarker Trials Baim Institute for Clinical Research Boston MA

Hospital CUF Descobertas Lisbon Portugal

Hospital Universitario Puerta de Hierro de Majadahonda IDIPHISA CIBERCV and Centro Nacional de Investigaciones Cardiovasculares Madrid Spain

Hypertrophic Cardiomyopathy Patient Author Zwolle The Netherlands

JV Cardiology Prague Czech Republic

Lahey Hospital and Medical Center Burlington MA

Leviev Heart Center Sheba Medical Center Ramat Gan and Tel Aviv University Ramat Gan Israel

Meyer Children's Hospital Istituto di Ricovero e Cura a Carattere Scientifico Florence Italy

National Institute of Cardiololgy Warsaw Poland

Northwestern University Feinberg School of Medicine Chicago IL

Oregon Health and Science University Portland OR

Radcliffe Department of Medicine University of Oxford United Kingdom

School of Cardiovascular and Metabolic Health University of Glasgow United Kingdom

Section of Forensic Genetics Department of Forensic Medicine Faculty of Health and Medical Sciences University of Copenhagen Denmark

University of California San Francisco San Francisco CA

University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute Kansas City MO

University of Pennsylvania Perelman School of Medicine Philadelphia PA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019390
003      
CZ-PrNML
005      
20241024110734.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1161/JAHA.124.035993 $2 doi
035    __
$a (PubMed)39056349
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Coats, Caroline J $u School of Cardiovascular and Metabolic Health University of Glasgow United Kingdom $1 https://orcid.org/000000023208470X
245    10
$a Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM / $c CJ. Coats, A. Masri, ME. Nassif, R. Barriales-Villa, M. Arad, N. Cardim, L. Choudhury, B. Claggett, HD. Düngen, P. Garcia-Pavia, AA. Hagège, JL. Januzzi, MMY. Lee, GD. Lewis, CS. Ma, MS. Maron, ZM. Miao, M. Michels, I. Olivotto, A. Oreziak, AT. Owens, JA. Spertus, SD. Solomon, J. Tfelt-Hansen, M. van Sinttruije, J. Veselka, H. Watkins, DL. Jacoby, P. German, SB. Heitner, S. Kupfer, JD. Lutz, FI. Malik, L. Meng, A. Wohltman, TP. Abraham, SEQUOIA‐HCM Investigators *
520    9_
$a BACKGROUND: Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of aficamten in SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). METHODS AND RESULTS: A total of 282 patients with obstructive hypertrophic cardiomyopathy were randomized 1:1 to daily aficamten (5-20 mg) or placebo between February 1, 2022, and May 15, 2023. Aficamten dosing targeted the lowest effective dose for achieving site-interpreted Valsalva left ventricular outflow tract gradient <30 mm Hg with left ventricular ejection fraction (LVEF) ≥50%. End points were evaluated during titration (day 1 to week 8), maintenance (weeks 8-24), and washout (weeks 24-28), and included major adverse cardiac events, new-onset atrial fibrillation, implantable cardioverter-defibrillator discharges, LVEF <50%, and treatment-emergent adverse events. At week 8, 3.6%, 12.9%, 35%, and 48.6% of patients achieved 5-, 10-, 15-, and 20-mg doses, respectively. Baseline characteristics were similar across groups. Aficamten concentration increased by dose and remained stable during maintenance. During the treatment period, LVEF decreased by -0.9% (95% CI, -1.3 to -0.6) per 100 ng/mL aficamten exposure. Seven (4.9%) patients taking aficamten underwent per-protocol dose reduction for site-interpreted LVEF <50%. There were no treatment interruptions or heart failure worsening for LVEF <50%. No major adverse cardiovascular events were associated with aficamten, and treatment-emergent adverse events were similar between treatment groups, including atrial fibrillation. CONCLUSIONS: A site-based dosing algorithm targeting the lowest effective aficamten dose reduced left ventricular outflow tract gradient with a favorable safety profile throughout SEQUOIA-HCM. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05186818.
650    _2
$a lidé $7 D006801
650    12
$a hypertrofická kardiomyopatie $x patofyziologie $x farmakoterapie $x diagnóza $7 D002312
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a funkce levé komory srdeční $x účinky léků $7 D016277
650    12
$a tepový objem $x účinky léků $7 D013318
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dospělí $7 D000328
650    _2
$a fibrilace síní $x farmakoterapie $x diagnóza $x patofyziologie $7 D001281
650    _2
$a benzylaminy $7 D001596
650    _2
$a uracil $x analogy a deriváty $7 D014498
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Masri, Ahmad $u Oregon Health and Science University Portland OR $1 https://orcid.org/0000000263906526
700    1_
$a Nassif, Michael E $u University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute Kansas City MO
700    1_
$a Barriales-Villa, Roberto $u Complexo Hospitalario Universitario A Coruña, INIBIC, CIBERCV-ISCIII A Coruña Spain $1 https://orcid.org/0000000267213487
700    1_
$a Arad, Michael $u Leviev Heart Center, Sheba Medical Center Ramat-Gan and Tel Aviv University Ramat-Gan Israel $1 https://orcid.org/0000000337237493
700    1_
$a Cardim, Nuno $u Hospital CUF Descobertas Lisbon Portugal $1 https://orcid.org/0000000238124872
700    1_
$a Choudhury, Lubna $u Northwestern University Feinberg School of Medicine Chicago IL $1 https://orcid.org/0000000340398490
700    1_
$a Claggett, Brian $u Cardiovascular Division Brigham and Women's Hospital, Harvard Medical School Boston MA $1 https://orcid.org/0000000242159218
700    1_
$a Düngen, Hans-Dirk $u Charité Campus Virchow-Klinikum Berlin Germany
700    1_
$a Garcia-Pavia, Pablo $u Hospital Universitario Puerta de Hierro de Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC) Madrid Spain $1 https://orcid.org/0000000254702257
700    1_
$a Hagège, Albert A $u Assistance Publique Hôpitaux de Paris, Département de Cardiologie, Hôpital Européen Georges-Pompidou Paris France $1 https://orcid.org/0000000346856077
700    1_
$a Januzzi, James L $u Division of Cardiology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA $u Heart Failure and Biomarker Trials Baim Institute for Clinical Research Boston MA $1 https://orcid.org/0000000283381798
700    1_
$a Lee, Matthew M Y $u School of Cardiovascular and Metabolic Health University of Glasgow United Kingdom $1 https://orcid.org/0000000192132067
700    1_
$a Lewis, Gregory D $u Division of Cardiology, Department of Medicine Massachusetts General Hospital, Harvard Medical School Boston MA $1 https://orcid.org/0000000181088240
700    1_
$a Ma, Chang-Sheng $u Beijing Anzhen Hospital, Capital Medical University Beijing China $1 https://orcid.org/0000000253875957
700    1_
$a Maron, Martin S $u Lahey Hospital and Medical Center Burlington MA $1 https://orcid.org/0000000299233853
700    1_
$a Miao, Zi Michael $u Cardiovascular Division Brigham and Women's Hospital, Harvard Medical School Boston MA $1 https://orcid.org/0000000223771444
700    1_
$a Michels, Michelle $u Department of Cardiology Erasmus Medical Center, Cardiovascular Institute, Thoraxcenter Rotterdam The Netherlands $1 https://orcid.org/0000000164320431
700    1_
$a Olivotto, Iacopo $u Meyer Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Florence Italy $1 https://orcid.org/0000000317519266
700    1_
$a Oreziak, Artur $u National Institute of Cardiololgy Warsaw Poland $1 https://orcid.org/0000000333183643
700    1_
$a Owens, Anjali T $u University of Pennsylvania Perelman School of Medicine Philadelphia PA $1 https://orcid.org/0000000296698495
700    1_
$a Spertus, John A $u University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute Kansas City MO $1 https://orcid.org/0000000228392611
700    1_
$a Solomon, Scott D $u Cardiovascular Division Brigham and Women's Hospital, Harvard Medical School Boston MA $1 https://orcid.org/0000000336989597
700    1_
$a Tfelt-Hansen, Jacob $u Section of Forensic Genetics, Department of Forensic Medicine, Faculty of Health and Medical Sciences University of Copenhagen Denmark $u Department of Cardiology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark $1 https://orcid.org/0000000338959316
700    1_
$a van Sinttruije, Marion $u Hypertrophic Cardiomyopathy Patient Author Zwolle The Netherlands
700    1_
$a Veselka, Josef $u JV Cardiology Prague Czech Republic
700    1_
$a Watkins, Hugh $u Radcliffe Department of Medicine University of Oxford United Kingdom $1 https://orcid.org/0000000252879016
700    1_
$a Jacoby, Daniel L $u Cytokinetics, Incorporated South San Francisco CA
700    1_
$a German, Polina $u Cytokinetics, Incorporated South San Francisco CA
700    1_
$a Heitner, Stephen B $u Cytokinetics, Incorporated South San Francisco CA $1 https://orcid.org/0000000321891474
700    1_
$a Kupfer, Stuart $u Cytokinetics, Incorporated South San Francisco CA $1 https://orcid.org/0000000254691287
700    1_
$a Lutz, Justin D $u Cytokinetics, Incorporated South San Francisco CA
700    1_
$a Malik, Fady I $u Cytokinetics, Incorporated South San Francisco CA $1 https://orcid.org/0000000255975759
700    1_
$a Meng, Lisa $u Cytokinetics, Incorporated South San Francisco CA
700    1_
$a Wohltman, Amy $u Cytokinetics, Incorporated South San Francisco CA
700    1_
$a Abraham, Theodore P $u University of California San Francisco San Francisco CA
710    2_
$a SEQUOIA‐HCM Investigators *
773    0_
$w MED00188127 $t Journal of the American Heart Association $x 2047-9980 $g Roč. 13, č. 15 (2024), s. e035993
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39056349 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110728 $b ABA008
999    __
$a ok $b bmc $g 2201931 $s 1231363
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 15 $d e035993 $e 20240726 $i 2047-9980 $m Journal of the American Heart Association $n J Am Heart Assoc $x MED00188127
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace